Literature DB >> 12727942

Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma.

Yasutaka Murata1, Hisao Ando, Tetsuro Nagasaka, Ikuo Takahashi, Kiyoshi Saito, Hiroyuki Fukugaki, Katsuji Matsuzawa, Shigehiko Mizutani.   

Abstract

Gonadotropin-producing pituitary adenomas are extremely rare in reproductive-age women. We report here a case of gonadotroph microadenoma with ovarian hyperstimulation. It was found in a 29-yr-old infertile Japanese woman with enlarged multicystic ovaries. The patient had an elevated basal serum estradiol level (up to 6755 pM, or 1840 pg/ml). Serum FSH and prolactin were mildly elevated (15.4 IU/liter, 1.4 nM or 31.4 ng/ml), whereas LH was low (0.5 IU/liter). The FSH level was paradoxically elevated in response to TRH administration. Dynamic magnetic resonance imaging revealed a pituitary microadenoma. Daily administration of bromocriptine, a dopamine agonist, normalized the ovarian size, and the patient ovulated naturally. She conceived after 3 months of bromocriptine therapy and delivered a normal child. She underwent elective transsphenoidal pituitary surgery, 3 yr after the delivery. Immunostaining of the resected tumor showed that 80% and less than 5% of the tumor cells stained for FSH-beta and prolactin, respectively. Furthermore, RT-PCR suggested that dopamine type 2 receptor was expressed in the adenoma. Gonadotroph microadenoma should be considered in women with spontaneous ovarian hyperstimulation, even if they have no neurological symptoms or marked pituitary enlargement. In such cases, bromocriptine therapy may be an alternative to pituitary surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727942     DOI: 10.1210/jc.2002-021820

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey.

Authors:  Z Karaca; S Yarman; I Ozbas; P Kadioglu; M Akturk; F Kilicli; H S Dokmetas; R Colak; H Atmaca; Z Canturk; Y Altuntas; N Ozbey; N Hatipoglu; F Tanriverdi; K Unluhizarci; F Kelestimur
Journal:  J Endocrinol Invest       Date:  2017-06-20       Impact factor: 4.256

Review 2.  Treatment of pituitary tumors: dopamine agonists.

Authors:  Gabriella Iván; Nikoletta Szigeti-Csúcs; Márk Oláh; György M Nagy; Miklós I Góth
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

3.  Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.

Authors:  T Miyoshi; F Otsuka; M Takeda; K Inagaki; J Suzuki; T Ogura; I Date; K Hashimoto; H Makino
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 4.  Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Renata S Auriemma; Carlo Alviggi; Ludovica F S Grasso; Alessia Cozzolino; Monica De Leo; Giuseppe De Placido; Annamaria Colao; Gaetano Lombardi
Journal:  J Endocrinol Invest       Date:  2014-01-16       Impact factor: 4.256

5.  Ovarian hyperstimulation syndrome due to follicle-stimulating hormone-secreting pituitary adenomas.

Authors:  Amelia Caretto; Roberto Lanzi; Cecilia Piani; Michela Molgora; Pietro Mortini; Marco Losa
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

6.  Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma.

Authors:  Odelia Cooper; Jordan L Geller; Shlomo Melmed
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-02-12

7.  Molecular analysis of a mutated FSH receptor detected in a patient with spontaneous ovarian hyperstimulation syndrome.

Authors:  Sayaka Uchida; Hiroshi Uchida; Tetsuo Maruyama; Takashi Kajitani; Hideyuki Oda; Kaoru Miyazaki; Maki Kagami; Yasunori Yoshimura
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

Review 8.  Updating the Landscape for Functioning Gonadotroph Tumors.

Authors:  Georgia Ntali; Cristina Capatina
Journal:  Medicina (Kaunas)       Date:  2022-08-08       Impact factor: 2.948

9.  Testicular "hyperstimulation" syndrome: a case of functional gonadotropinoma.

Authors:  Astha Thakkar; Subramanian Kannan; Amir Hamrahian; Richard A Prayson; Robert J Weil; Charles Faiman
Journal:  Case Rep Endocrinol       Date:  2014-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.